Research ExplorerPublicationsHypertension delays viral clearance and exacerbates airway h...

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Standard

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. / Trump, Saskia; Lukassen, Soeren; Anker, Markus S; Chua, Robert Lorenz; Liebig, Johannes; Thürmann, Loreen; Corman, Victor Max; Binder, Marco; Loske, Jennifer; Klasa, Christina; Krieger, Teresa; Hennig, Bianca P; Messingschlager, Marey; Pott, Fabian; Kazmierski, Julia; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jürgen; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Bürgel, Thore; Steinfeldt, Jakob; Goffinet, Christine; Kurth, Florian; Witzenrath, Martin; Völker, Maria Theresa; Müller, Sarah Dorothea; Liebert, Uwe Gerd; Ishaque, Naveed; Kaderali, Lars; Sander, Leif-Erik; Drosten, Christian; Laudi, Sven; Eils, Roland; Conrad, Christian; Landmesser, Ulf; Lehmann, Irina.

In: NAT BIOTECHNOL, Vol. 39, No. 6, 06.2021, p. 705-716.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Trump, S, Lukassen, S, Anker, MS, Chua, RL, Liebig, J, Thürmann, L, Corman, VM, Binder, M, Loske, J, Klasa, C, Krieger, T, Hennig, BP, Messingschlager, M, Pott, F, Kazmierski, J, Twardziok, S, Albrecht, JP, Eils, J, Hadzibegovic, S, Lena, A, Heidecker, B, Bürgel, T, Steinfeldt, J, Goffinet, C, Kurth, F, Witzenrath, M, Völker, MT, Müller, SD, Liebert, UG, Ishaque, N, Kaderali, L, Sander, L-E, Drosten, C, Laudi, S, Eils, R, Conrad, C, Landmesser, U & Lehmann, I 2021, 'Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19', NAT BIOTECHNOL, vol. 39, no. 6, pp. 705-716. https://doi.org/10.1038/s41587-020-00796-1

APA

Trump, S., Lukassen, S., Anker, M. S., Chua, R. L., Liebig, J., Thürmann, L., Corman, V. M., Binder, M., Loske, J., Klasa, C., Krieger, T., Hennig, B. P., Messingschlager, M., Pott, F., Kazmierski, J., Twardziok, S., Albrecht, J. P., Eils, J., Hadzibegovic, S., ... Lehmann, I. (2021). Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. NAT BIOTECHNOL, 39(6), 705-716. https://doi.org/10.1038/s41587-020-00796-1

Vancouver

Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. NAT BIOTECHNOL. 2021 Jun;39(6):705-716. https://doi.org/10.1038/s41587-020-00796-1

Bibtex

@article{245392067fb54b1eb3f4c004c73094b9,
title = "Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19",
abstract = "In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.",
keywords = "Adult, Angiotensin Receptor Antagonists/administration & dosage, Angiotensin-Converting Enzyme Inhibitors/administration & dosage, COVID-19/complications, Chemokine CCL3/genetics, Chemokine CCL4/genetics, Disease Progression, Female, Gene Expression Regulation/drug effects, Humans, Hypertension/complications, Inflammation/complications, Male, Middle Aged, RNA-Seq, Receptors, CCR1/genetics, Respiratory System/drug effects, Risk Factors, SARS-CoV-2/pathogenicity, Single-Cell Analysis",
author = "Saskia Trump and Soeren Lukassen and Anker, {Markus S} and Chua, {Robert Lorenz} and Johannes Liebig and Loreen Th{\"u}rmann and Corman, {Victor Max} and Marco Binder and Jennifer Loske and Christina Klasa and Teresa Krieger and Hennig, {Bianca P} and Marey Messingschlager and Fabian Pott and Julia Kazmierski and Sven Twardziok and Albrecht, {Jan Philipp} and J{\"u}rgen Eils and Sara Hadzibegovic and Alessia Lena and Bettina Heidecker and Thore B{\"u}rgel and Jakob Steinfeldt and Christine Goffinet and Florian Kurth and Martin Witzenrath and V{\"o}lker, {Maria Theresa} and M{\"u}ller, {Sarah Dorothea} and Liebert, {Uwe Gerd} and Naveed Ishaque and Lars Kaderali and Leif-Erik Sander and Christian Drosten and Sven Laudi and Roland Eils and Christian Conrad and Ulf Landmesser and Irina Lehmann",
year = "2021",
month = jun,
doi = "10.1038/s41587-020-00796-1",
language = "English",
volume = "39",
pages = "705--716",
journal = "NAT BIOTECHNOL",
issn = "1087-0156",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

AU - Trump, Saskia

AU - Lukassen, Soeren

AU - Anker, Markus S

AU - Chua, Robert Lorenz

AU - Liebig, Johannes

AU - Thürmann, Loreen

AU - Corman, Victor Max

AU - Binder, Marco

AU - Loske, Jennifer

AU - Klasa, Christina

AU - Krieger, Teresa

AU - Hennig, Bianca P

AU - Messingschlager, Marey

AU - Pott, Fabian

AU - Kazmierski, Julia

AU - Twardziok, Sven

AU - Albrecht, Jan Philipp

AU - Eils, Jürgen

AU - Hadzibegovic, Sara

AU - Lena, Alessia

AU - Heidecker, Bettina

AU - Bürgel, Thore

AU - Steinfeldt, Jakob

AU - Goffinet, Christine

AU - Kurth, Florian

AU - Witzenrath, Martin

AU - Völker, Maria Theresa

AU - Müller, Sarah Dorothea

AU - Liebert, Uwe Gerd

AU - Ishaque, Naveed

AU - Kaderali, Lars

AU - Sander, Leif-Erik

AU - Drosten, Christian

AU - Laudi, Sven

AU - Eils, Roland

AU - Conrad, Christian

AU - Landmesser, Ulf

AU - Lehmann, Irina

PY - 2021/6

Y1 - 2021/6

N2 - In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.

AB - In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.

KW - Adult

KW - Angiotensin Receptor Antagonists/administration & dosage

KW - Angiotensin-Converting Enzyme Inhibitors/administration & dosage

KW - COVID-19/complications

KW - Chemokine CCL3/genetics

KW - Chemokine CCL4/genetics

KW - Disease Progression

KW - Female

KW - Gene Expression Regulation/drug effects

KW - Humans

KW - Hypertension/complications

KW - Inflammation/complications

KW - Male

KW - Middle Aged

KW - RNA-Seq

KW - Receptors, CCR1/genetics

KW - Respiratory System/drug effects

KW - Risk Factors

KW - SARS-CoV-2/pathogenicity

KW - Single-Cell Analysis

U2 - 10.1038/s41587-020-00796-1

DO - 10.1038/s41587-020-00796-1

M3 - SCORING: Journal article

C2 - 33361824

VL - 39

SP - 705

EP - 716

JO - NAT BIOTECHNOL

JF - NAT BIOTECHNOL

SN - 1087-0156

IS - 6

ER -